United Kingdom
Key Insights
- 1
No psychedelic is approved for routine NHS use; ketamine and, in rare cases, esketamine are used off-label or under specialist services, while psilocybin, MDMA and LSD remain research-only.
- 2
The UK tracks 64 psychedelic trials, with 11 active; psilocybin leads the pipeline, alongside ketamine, esketamine, LSD and DMT in active studies.
- 3
Britain helped define modern psychedelic science: Imperial College London launched the world’s first Centre for Psychedelic Research in 2019.
- 4
Momentum is centred on Imperial and NHS-linked studies, including a 2026 DMT depression readout and a first UK psilocybin trial in opioid addiction, backed by NIHR and government funding.
Reimbursed Care Access
TBD executive summary
Quick Indicators
Organizations
45Alef Trust
United Kingdom
Alexander Mosely Charitable Trust
United Kingdom
AstraZeneca
United Kingdom
AtaiBeckley
New York, NY (HQ)
Awakn
United Kingdom
Beckley Psytech
London / Oxford
British Transpersonal Association
United Kingdom
COMPASS Pathways
United Kingdom
Cambridge Cognition Ltd
United Kingdom
Cambridge Psychedelic Research Group
University of Cambridge
Chief Scientist Office of the Scottish Government
United Kingdom
Clerkenwell Health
United Kingdom
Drug Science
London, United Kingdom
Exeter Psychedelic Research Group
University of Exeter
Exeter University
United Kingdom
Hammersmith Medicines Research
United Kingdom
Helus Pharma
Toronto, ON
IAI Academy
United Kingdom
Idler
United Kingdom
Imperial College London
United Kingdom
Institute of Psychedelic Therapy
United Kingdom
King's College London
United Kingdom
MAC Clinical Research
United Kingdom
MHRA Yellow Card
Maps of the Mind
United Kingdom
Medical Research Council
United Kingdom
Medicines and Healthcare products Regulatory Agency (MHRA)
NHS Grampian
United Kingdom
National Institute for Health Research, United Kingdom
United Kingdom
National Institute for Health and Care Excellence (NICE)
National Institute for Health and Care Research (NIHR)
Neurocentrx
Office for Product Safety and Standards (OPSS)
Otsuka Pharmaceutical
2-9 Kanda Tsukasa-cho, Chiyoda-ku, Tokyo 101-8535, Japan
PsyCare UK
Psyrin Inc.
United Kingdom
Save Minds at Smart Clinics
United Kingdom
Scottish Medicines Consortium (SMC)
Small Pharma Ltd
United Kingdom
Solvonis Therapeutics
Eccleston Yards, 25 Eccleston Place, London SW1W 9NF, UK
South London and Maudsley NHS Foundation Trust
United Kingdom
University College London
United Kingdom
University of Cambridge
United Kingdom
University of Greenwich
Old Royal Naval College, Park Row, London SE10 9LS
University of Manchester
United Kingdom
Research Events
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in United Kingdom.